{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:54:52Z","timestamp":1784289292390,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the National Cancer Center Research and Development Fund","award":["29-A-14"],"award-info":[{"award-number":["29-A-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s12185-020-02960-4","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T19:09:21Z","timestamp":1596481761000},"page":"674-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study"],"prefix":"10.1007","volume":"112","author":[{"given":"Ayumu","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Katsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonari","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Togitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"2960_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet (Engl). 2002;359:2065\u201371.","journal-title":"Lancet (Engl)"},{"key":"2960_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the lymphoma working party of the European group for blood and marrow transplantation. Haematologica. 2012;97:310\u20137.","journal-title":"Haematologica"},{"key":"2960_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ajh.23897","volume":"90","author":"S Kako","year":"2015","unstructured":"Kako S, Izutsu K, Kato K, Kim SW, Mori T, Fukuda T, et al. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Am J Hematol. 2015;90:132\u20138.","journal-title":"Am J Hematol"},{"key":"2960_CR4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","volume":"27","author":"S Genadieva-Stavrik","year":"2016","unstructured":"Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the lymphoma working party of the european group for blood and marrow transplantation. Ann Oncol. 2016;27:2251\u20137.","journal-title":"Ann Oncol"},{"key":"2960_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/bmt.2015.332","volume":"51","author":"A Rashidi","year":"2016","unstructured":"Rashidi A, Ebadi M, Cashen AF. Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2016;51:521\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR6","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clini Oncol. 2017;35:2125\u201332.","journal-title":"J Clini Oncol"},{"key":"2960_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/cas.13230","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci. 2017;108:1007\u2013122.","journal-title":"Cancer Sci"},{"key":"2960_CR8","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase ii checkmate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"2960_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2019.04.006","volume":"115","author":"G Manson","year":"2019","unstructured":"Manson G, Mear JB, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer (Oxford, England : 1990). 2019;115:47\u201356.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"2960_CR10","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","volume":"131","author":"G Manson","year":"2018","unstructured":"Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, et al. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood. 2018;131:2856\u20139.","journal-title":"Blood"},{"key":"2960_CR11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","volume":"129","author":"RW Merryman","year":"2017","unstructured":"Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma. Blood. 2017;129:1380\u20138.","journal-title":"Blood"},{"key":"2960_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221\u20138.","journal-title":"Blood"},{"key":"2960_CR13","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471\u20138.","journal-title":"Blood"},{"key":"2960_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/bmt.2017.69","volume":"52","author":"J El Cheikh","year":"2017","unstructured":"El Cheikh J, Massoud R, Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1074\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41409-018-0310-6","volume":"54","author":"M Kuno","year":"2019","unstructured":"Kuno M, Ito A, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, et al. Severe immune-related complications early after allogeneic hematopoietic cell transplantation for nivolumab-pretreated lymphoma. Bone Marrow Transplant. 2019;54:473\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","volume":"132","author":"C Herbaux","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S, Armand P, Houot R, Morschhauser F, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018;132:9\u201316.","journal-title":"Blood"},{"key":"2960_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2960_CR18","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2960_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","volume":"27","author":"TR Spitzer","year":"2001","unstructured":"Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:893\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389\u2013401.el.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2960_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"2960_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2960_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2960_CR26","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2018-99-114887","volume":"132","author":"JC Nieto","year":"2018","unstructured":"Nieto JC, Roldan E, Jim\u00e9nez I, Fox L, Carabia J, Orti G, et al. Graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCY) induces a more tolerant immune response after allogeneic hematopoietic cell transplantation (Allo-HCT) in patients previously exposed to nivolumab. Blood. 2018;132:3402.","journal-title":"Blood"},{"key":"2960_CR27","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1182\/bloodadvances.2018019208","volume":"2","author":"LK Schoch","year":"2018","unstructured":"Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood advances. 2018;2:2226\u20139.","journal-title":"Blood advances"},{"key":"2960_CR28","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","volume":"4","author":"C De Philippis","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S, Giordano L, Montes de Oca C, Dulery R, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood advances. 2020;4:1242\u20139.","journal-title":"Blood advances."},{"issue":"10","key":"2960_CR29","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.32796","volume":"126","author":"B Oran","year":"2020","unstructured":"Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors. Cancer. 2020;126(10):2193\u2013205.","journal-title":"Cancer"},{"key":"2960_CR30","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","volume":"129","author":"CG Kanakry","year":"2017","unstructured":"Kanakry CG, Bolanos-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, et al. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood. 2017;129:1389\u201393.","journal-title":"Blood"},{"key":"2960_CR31","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2016-06-723205","volume":"128","author":"R Greco","year":"2016","unstructured":"Greco R, Lorentino F, Morelli M, Giglio F, Mannina D, Assanelli A, et al. Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation. Blood. 2016;128:1528\u201331.","journal-title":"Blood"},{"key":"2960_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ejh.12541","volume":"96","author":"U Holtick","year":"2016","unstructured":"Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27\u201335.","journal-title":"Eur J Haematol"},{"key":"2960_CR33","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"C Martinez","year":"2017","unstructured":"Martinez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the lymphoma working party of the european society for blood and marrow transplantation. J Clin Oncol. 2017;35:3425\u201332.","journal-title":"J Clin Oncol"},{"key":"2960_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease Compared with HLA-identical related donors. Biol Blood Marrow Transplant. 2018;24:627\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2960_CR35","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.bbmt.2019.05.017","volume":"25","author":"J Mariotti","year":"2019","unstructured":"Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. Peripheral blood stem cells versus bone marrow for T Cell-Replete haploidentical transplantation with post-transplant cyclophosphamide in hodgkin lymphoma. Biol Blood Marrow Transplant. 2019;25:1810\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2960_CR36","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","volume":"98","author":"A Bacigalupo","year":"2001","unstructured":"Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942\u20137.","journal-title":"Blood"},{"key":"2960_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"2960_CR38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164\u201373.","journal-title":"Lancet Oncol"},{"key":"2960_CR39","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, et al. Prospective, randomized, double-blind, phase iii clinical trial of anti-t-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017;35:4003\u2013111.","journal-title":"J Clin Oncol"},{"key":"2960_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12185-018-02584-9","volume":"109","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Guo YM, Yamashita T, Nara M, Yoshioka T, Kameoka Y, et al. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2019;109:356\u201360.","journal-title":"Int J Hematol"},{"key":"2960_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0000000000000341","volume":"27","author":"H Blasig","year":"2017","unstructured":"Blasig H, Bender C, Hassel JC, Eigentler TK, Sachse MM, Hiernickel J, et al. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res. 2017;27:321\u20135.","journal-title":"Melanoma Res"},{"key":"2960_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-017-0273-y","volume":"5","author":"DJ Martini","year":"2017","unstructured":"Martini DJ, Lalani AA, Bosse D, Steinharter JA, Harshman LC, Hodi FS, et al. Response to single agent PD-1 inhibitor after progression on previous PD-1\/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017;5:66.","journal-title":"J Immunother Cancer"},{"key":"2960_CR43","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","volume":"81","author":"K Fujita","year":"2018","unstructured":"Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81:1105\u20139.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02960-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02960-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02960-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:32:47Z","timestamp":1650537167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02960-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["2960"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02960-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}